Stock Price Movement and Market Context
On the trading day, Remedium Lifecare Ltd’s share price fell by 2.63%, underperforming its sector by 3.48%. This decline extends a losing streak that has persisted for six consecutive trading sessions, during which the stock has lost 21.28% in value. The current price of Rs.0.37 is substantially lower than its 52-week high of Rs.1.94, reflecting a steep depreciation of 80.9% over the past year.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. This technical positioning aligns with the broader market environment, where the Sensex, despite gaining 1.1% on the day to close at 75,025.02, remains 4.8% above its own 52-week low of 71,425.01 and is trading below its 50-day moving average.
Financial Performance and Profitability Concerns
Remedium Lifecare Ltd’s financial metrics reveal ongoing challenges. The company reported a net sales decline of 65.79% in the most recent quarter, with net sales falling to Rs.8.58 crores. Profit after tax (PAT) for the nine-month period stands at a loss of Rs.2.94 crores, reflecting a contraction of 92.82% compared to prior periods. Earnings before interest, taxes, depreciation and amortisation (EBITDA) remain negative, contributing to a high Debt to EBITDA ratio of -1.00 times, indicating limited capacity to service debt obligations.
Operating profit growth has stagnated over the last five years, registering an annual growth rate of 0%, while the company has reported losses for five consecutive quarters. The negative return on capital employed (ROCE) further underscores the company’s inability to generate adequate returns from its capital base.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Long-Term and Recent Performance Trends
Over the past year, Remedium Lifecare Ltd’s stock has delivered a negative return of 74.88%, significantly underperforming the Sensex, which declined by only 1.70% during the same period. The stock’s performance has also lagged behind the BSE500 index over the last three years, one year, and three months, indicating persistent underperformance relative to broader market benchmarks.
The company’s quarterly profit before tax excluding other income (PBT less OI) has deteriorated sharply, falling by 293.90% to a loss of Rs.3.18 crores. This decline highlights the ongoing pressure on core earnings and operational cash flows.
Technical Indicators and Market Sentiment
Technical analysis of Remedium Lifecare Ltd’s stock reveals predominantly bearish signals. The Moving Average Convergence Divergence (MACD) indicator is bearish on a weekly basis, while monthly readings are mildly bullish but lack conviction. The Relative Strength Index (RSI) shows no clear signal on either weekly or monthly charts. Bollinger Bands indicate bearish trends on both weekly and monthly timeframes, and the Know Sure Thing (KST) indicator aligns with bearish momentum. Dow Theory assessments are mildly bearish across weekly and monthly periods.
These technical factors, combined with the stock’s position below all major moving averages, reinforce the current downward trajectory.
Institutional Shareholding and Market Participation
Institutional investors have marginally increased their stake in Remedium Lifecare Ltd by 1.7% over the previous quarter, collectively holding 1.7% of the company’s shares. This modest increase in institutional participation suggests some level of interest from investors with greater analytical resources, despite the company’s challenging financial profile.
Considering Remedium Lifecare Ltd? Wait! SwitchER has found potentially better options in Trading & Distributors and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Trading & Distributors + beyond scope
- - Top-rated alternatives ready
Sector and Market Comparison
Remedium Lifecare Ltd operates within the Trading & Distributors sector, which has seen mixed performance relative to the broader market. On the day of the stock’s new low, the Sensex was led by mega-cap stocks, contributing to a 1.1% gain. However, Remedium Lifecare’s micro-cap status and financial metrics have resulted in a divergence from this positive market trend.
The company’s Mojo Score of 1.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 9 Apr 2024, reflect the cautious stance adopted by rating agencies based on its financial health and market performance.
Summary of Key Financial and Market Metrics
To summarise, Remedium Lifecare Ltd’s key metrics as of 20 Mar 2026 are:
- New 52-week and all-time low price: Rs.0.37
- One-year stock return: -74.88%
- Net sales decline (quarterly): -65.79% to Rs.8.58 crores
- PAT (9 months): Rs.-2.94 crores, down 92.82%
- PBT less other income (quarterly): Rs.-3.18 crores, down 293.90%
- Debt to EBITDA ratio: -1.00 times
- Mojo Grade: Strong Sell (upgraded from Sell on 9 Apr 2024)
- Market cap grade: Micro-cap
The stock’s technical and fundamental indicators collectively point to a challenging environment for Remedium Lifecare Ltd, with continued pressure on price levels and financial performance.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
